EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib Suzanne Jenkins, DPhil, James Chih-Hsin.

Slides:

Advertisements

Similar presentations

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Advertisements

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers Christos.

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

Pharmacogenetic Analysis of BR

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer David R. Spigel,

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer Suzanne Jenkins, DPhil, James C-H.

A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next- Generation.

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib Helena A. Yu,

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

George Blumenschein, MD, John V. Heymach, MD, PhD

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Journal of Thoracic Oncology

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung.

Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib Nuria Chic, MD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program Solange.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib Suzanne Jenkins, DPhil, James Chih-Hsin Yang, M.B.B.S., MD, Pasi A. Jänne, MD, PhD, Kenneth S. Thress, PhD, Karen Yu, BA, Rachel Hodge, MSc, Susie Weston, BSc, Simon Dearden, MSc, Sabina Patel, PhD, Mireille Cantarini, MD, Frances A. Shepherd, MD Journal of Thoracic Oncology Volume 12, Issue 8, Pages 1247-1256 (August 2017) DOI: 10.1016/j.jtho.2017.05.002 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Disposition of tissue samples in the AURA extension and AURA2 studies. IUO, investigational use only. Journal of Thoracic Oncology 2017 12, 1247-1256DOI: (10.1016/j.jtho.2017.05.002) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 EGFR mutations detected in patients screened for pooled phase II studies (AURA extension and AURA2), stratified according to immediately prior EGFR tyrosine kinase inhibitor therapy (n = 486, which includes patients with a valid cobas EGFR Mutation test and who received either gefitinib, erlotinib or afatinib as an immediate prior therapy. A small number of T790M positive samples contained co-occurring G719X [gefitinib, n = 1; erlotinib, n = 4; afatinib, n = 2], and/or other EGFR mutations [gefitinib, n = 3; erlotinib, n = 2; afatinib, n = 2]). Journal of Thoracic Oncology 2017 12, 1247-1256DOI: (10.1016/j.jtho.2017.05.002) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions